NHS England on Oxbryta (Voxelotor) Withdrawal From the UK Market | National Haemoglobinopathy Panel | NHP Haemoglobinopathy England | Sickle Cell Thalassaemia | Rare Inherited Anaemia UK | NHP Haemoglobinopathy England | Sickle Cell Thalassaemia | Rare Inherited Anaemia UK

posted 4th October 2024

Posted 2 years ago

By NHS England

Publications New Therapies General Publications
NHS England on Oxbryta (Voxelotor) Withdrawal From the UK Market | National Haemoglobinopathy Panel | NHP Haemoglobinopathy England | Sickle Cell Thalassaemia | Rare Inherited Anaemia UK | NHP Haemoglobinopathy England | Sickle Cell Thalassaemia | Rare Inherited Anaemia UK

NHS England Letter to Centres regarding the Withdrawal of Pfizer's Oxbryta (Voxelotor) drug for Sickle Cell Disorder.